Next earnings date: 28 Oct 2025
Daiichi Sankyo Company, Limited – OTC:DSKYF
Daiichi Sankyo Company, Limited stock price today
$25.91
-0.83
-3.14%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Daiichi Sankyo Company, Limited stock price monthly change
-24.82%
month
Daiichi Sankyo Company, Limited stock price quarterly change
-24.82%
quarter
Daiichi Sankyo Company, Limited stock price yearly change
-0.37%
year
Daiichi Sankyo Company, Limited key metrics
Market Cap | 59.88B |
Enterprise value | 7.29T |
P/E | 35.26 |
EV/Sales | 4.32 |
EV/EBITDA | 23.17 |
Price/Sales | 4.74 |
Price/Book | 4.69 |
PEG ratio | N/A |
EPS | 33.46 |
Revenue | 1.27T |
EBITDA | 54.73B |
Income | 64.16B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 13.58% |
Oper. margin | 12.22% |
Gross margin | 75.3% |
EBIT margin | 12.22% |
EBITDA margin | 4.3% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDaiichi Sankyo Company, Limited stock price history
Daiichi Sankyo Company, Limited stock forecast
Daiichi Sankyo Company, Limited financial statements
| Dec 2021 | 281.00B | 31.85B | 11.34% |
|---|---|---|---|
| Mar 2022 | 233.92B | -27.34B | -11.69% |
| Mar 2023 | 330.20B | 22.48B | 6.81% |
| Mar 2024 | 428.41B | 37.16B | 8.68% |
| 2026 | 1.88T | 237.94B | 12.59% |
|---|---|---|---|
| 2027 | 2.20T | 337.06B | 15.28% |
| 2028 | 2.65T | 495.90B | 18.68% |
| 2029 | 2.94T | 536.13B | 18.18% |
Analysts Price target
Financials & Ratios estimates
1.51%
Yield TTM
| Payout ratio | 41.93% |
|---|
| 2020 | 0.95% |
|---|---|
| 2021 | 0.77% |
| 2022 | 1.03% |
| 2023 | 0.58% |
| 2024 | 0.73% |
| Sep 2022 | 2427775000000 | 960.62B | 39.57% |
|---|---|---|---|
| Dec 2022 | 2398031000000 | 983.70B | 41.02% |
| Mar 2023 | 2508889000000 | 1.05T | 42.13% |
| Mar 2024 | 3461135000000 | 1.76T | 50.94% |
| Dec 2021 | 69.67B | -16.04B | -29.88B |
|---|---|---|---|
| Mar 2022 | 38.08B | 39.81B | -3.59B |
| Mar 2023 | 32.37B | 17.69B | -3.79B |
| Mar 2024 | 29.96B | -63.40B | -3.83B |
Daiichi Sankyo Company, Limited alternative data
| Aug 2023 | 17,435 |
|---|---|
| Sep 2023 | 17,435 |
| Oct 2023 | 17,435 |
| Nov 2023 | 17,435 |
| Dec 2023 | 17,435 |
| Jan 2024 | 17,435 |
| Feb 2024 | 17,435 |
| Mar 2024 | 17,435 |
| Apr 2024 | 17,435 |
| May 2024 | 17,435 |
| Jun 2024 | 17,435 |
| Jul 2024 | 18,726 |
Daiichi Sankyo Company, Limited other data
| Quarter | Transcript |
|---|---|
| Q4 2023 25 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Feb 2024 | Q3 2023 Earnings Call Transcript |
| Q1 2023 31 Jul 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 1 May 2023 | Q4 2022 Earnings Call Transcript |
Why Novartis Is Still A 'Buy' After 15% Surge
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
Merck Proves Why It's Still A Top Pharma Pick
Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline
How To Pick Top Pharma Stocks: Novo Nordisk And More
Pfizer: Seriously Undervalued At Peak Pessimism
Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
-
What's the price of Daiichi Sankyo Company, Limited stock today?
One share of Daiichi Sankyo Company, Limited stock can currently be purchased for approximately $25.91.
-
When is Daiichi Sankyo Company, Limited's next earnings date?
Daiichi Sankyo Company, Limited is estimated to report earnings on Tuesday, 28 Oct 2025.
-
Does Daiichi Sankyo Company, Limited pay dividends?
Yes, Daiichi Sankyo Company, Limited pays dividends and its trailing 12-month yield is 1.51% with 42% payout ratio. The last Daiichi Sankyo Company, Limited stock dividend of undefined was paid on 25 Sep 2025.
-
How much money does Daiichi Sankyo Company, Limited make?
Daiichi Sankyo Company, Limited has a market capitalization of 59.88B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 25.28% to 1.6T US dollars.
-
What is Daiichi Sankyo Company, Limited's stock symbol?
Daiichi Sankyo Company, Limited is traded on the OTC under the ticker symbol "DSKYF".
-
What is Daiichi Sankyo Company, Limited's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers—General industry.
-
How do i buy shares of Daiichi Sankyo Company, Limited?
Shares of Daiichi Sankyo Company, Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Daiichi Sankyo Company, Limited have?
As Jul 2024, Daiichi Sankyo Company, Limited employs 18,726 workers, which is 7% more then previous month and 7% more then previous quarter.
-
When Daiichi Sankyo Company, Limited went public?
Daiichi Sankyo Company, Limited is publicly traded company for more then 17 years since IPO on 24 Jun 2008.
-
What is Daiichi Sankyo Company, Limited's official website?
The official website for Daiichi Sankyo Company, Limited is daiichisankyo.com.
-
How can i contact Daiichi Sankyo Company, Limited?
Daiichi Sankyo Company, Limited can be reached via phone at +81 3 6225 1111.
Daiichi Sankyo Company, Limited company profile:
Daiichi Sankyo Company, Limited
daiichisankyo.comExchange:
OTC
Full time employees:
16,458
Industry:
Drug Manufacturers—General
Sector:
Healthcare
Daiichi Sankyo Company, Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; and ferric carboxymaltose injection for treating anemia. It also provides edoxaban, an oral, once-daily, direct factor Xa inhibitor; esaxerenone and olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastases from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company was founded in 1899 and is headquartered in Tokyo, Japan.
3-5-1, Nihonbashi-honcho
Tokyo, 103-8426
Tokyo, 103-8426
:
:
:
